Scynexis (SCYX) Receivables - Other (2013 - 2025)
Scynexis' (SCYX) quarterly Receivables - Other came in at $9.5 million in Q1 2025, down 51.15% on a YoY basis from $19.5 million in Q1 2024, and little changed quarter-over-quarter from $9.5 million in Q4 2024.
Analysis
Scynexis (SCYX) Receivables - Other (2013 - 2025) Analysis & Trends
Scynexis (SCYX) has reported Receivables - Other for 11 consecutive years, with $9.5 million the latest figure, recorded in Q1 2025.
- For the quarter ending Q1 2025, Receivables - Other fell 51.15% year-over-year to $9.5 million; the trailing twelve-month figure through Mar 2025 stood at $9.5 million (down 51.15% YoY), and the FY2024 full-year result was $9.5 million, down 50.89% from the prior year.
- Receivables - Other steadied at $9.5 million in Q1 2025 per SCYX's latest filing, from $9.5 million in the prior quarter.
- Across five years, Receivables - Other topped out at $19.5 million in Q2 2024 and bottomed at $1.0 million in Q1 2021.
- Historically, Receivables - Other has averaged $14.0 million across 4 years, with a median of $19.2 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Receivables - Other advanced 1.35% in 2024, then slumped 51.15% in 2025.
- Over 4 years, Receivables - Other stood at $1.0 million in 2021, then jumped by 1836.3% to $19.4 million in 2023, then tumbled by 50.89% to $9.5 million in 2024, then changed by 0.0% to $9.5 million in 2025.
- According to Business Quant data, Receivables - Other over the past three periods registered $9.5 million, $9.5 million, and $9.5 million for Q1 2025, Q4 2024, and Q3 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 9.51 Mn |
| Dec 31, 2024 | 9.51 Mn |
| Sep 30, 2024 | 9.51 Mn |
| Jun 30, 2024 | 19.51 Mn |
| Mar 31, 2024 | 19.47 Mn |
| Dec 31, 2023 | 19.36 Mn |
| Sep 30, 2023 | 19.31 Mn |
| Jun 30, 2023 | 19.25 Mn |
| Mar 31, 2021 | 1.00 Mn |
| Dec 31, 2020 | 2.88 Mn |
| Sep 30, 2018 | 175,000.00 |
| Jun 30, 2018 | 175,000.00 |
| Mar 31, 2018 | 251,000.00 |
| Dec 31, 2017 | 251,000.00 |
| Sep 30, 2017 | 251,000.00 |
| Jun 30, 2017 | 300,000.00 |
| Mar 31, 2017 | 300,000.00 |
| Dec 31, 2016 | 233,000.00 |
| Sep 30, 2016 | 1.02 Mn |
| Jun 30, 2016 | 816,000.00 |